Overall, one third of the 2,087 study participants
achieved escitalopram blood levels that were either too high or too low.
«Our study shows that genotyping of CYP2C19 could be of considerable clinical value in individualising doses of
escitalopram so that a better all - round antidepressive effect could be
achieved for the patients,» says Professor Magnus Ingelman - Sundberg at Karolinska Institutet's Department of Physiology and Pharmacology who led the study together with Professor Espen Molden.